APA (7th ed.) Citation

Rodriguez, T. E., Hari, P., Stiff, P. J., Smith, S. E., Sterrenberg, D., & Vesole, D. H. (2016). Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Biology of blood and marrow transplantation, 22(8), 1391-1396. https://doi.org/10.1016/j.bbmt.2016.03.021

Chicago Style (17th ed.) Citation

Rodriguez, Tulio E., Parameswaran Hari, Patrick J. Stiff, Scott E. Smith, Danielle Sterrenberg, and David H. Vesole. "Busulfan, Melphalan, and Bortezomib Versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma." Biology of Blood and Marrow Transplantation 22, no. 8 (2016): 1391-1396. https://doi.org/10.1016/j.bbmt.2016.03.021.

MLA (9th ed.) Citation

Rodriguez, Tulio E., et al. "Busulfan, Melphalan, and Bortezomib Versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma." Biology of Blood and Marrow Transplantation, vol. 22, no. 8, 2016, pp. 1391-1396, https://doi.org/10.1016/j.bbmt.2016.03.021.